Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Kleo Papaparaskeva
Based on 3 articles published since 2010
(Why 3 articles?)

Between 2010 and 2020, Kleo Papaparaskeva wrote the following 3 articles about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Review Positive para-aortic lymph nodes following pancreatectomy for pancreatic cancer. Systematic review and meta-analysis of impact on short term survival and association with clinicopathologic features. 2016

Agalianos, Christos / Gouvas, Nikolaos / Papaparaskeva, Kleo / Dervenis, Christos. ·Athens Naval and Veterans Hospital, Department of Surgery, Athens, Greece. Electronic address: xagali@gmail.com. · "Konstantopouleio" Hospital of Athens, Department of Surgery, Athens, Greece. · "Konstantopouleio" Hospital of Athens, Department of Pathology, Athens, Greece. ·HPB (Oxford) · Pubmed #27485057.

ABSTRACT: BACKGROUND: The relation between para-aortic lymph nodes (PALN) involvement and pancreatic ductal adenocarcinoma (PDAC) survival, along with the optimal handling of this particular lymph node station remain unclear. A systematic review and meta-analysis was performed to assess this. METHODS: A search of Medline, Embase, Ovid and Cochrane databases was performed until July 2015 to identify studies reporting on the relation of PALN involvement and PDAC outcomes and a meta-analysis was performed following data extraction. RESULTS: Ten retrospective studies and two prospective non randomized studies (2467 patients) were included. Patients with positive PALN had worse one (p < 0.00001) and two year (p < 0.00001) survival when compared with patients with negative PALN. Even when comparing only patients with positive lymph nodes (N1), patients with PALN involvement presented with a significant lower one (p = 0.03) and two (p = 0.002) year survival. PALN involvement was associated with an increased possibility of positive margin (R1) resection (p < 0.00001), stations' 12, 14 and 17 malignant infiltration (p < 0.00001), but not with tumour stage (p = 0.78). DISCUSSION: Involvement of PALN is associated with decreased survival in pancreatic cancer patients. However, existence of long term survivors among this subgroup of patients should be further evaluated, in order to identify factors associated with their favourable prognosis.

2 Review Pancreatic neuroendocrine tumors: current opinions on a rare, but potentially curable neoplasm. 2014

Karakaxas, Dimitrios / Gazouli, Maria / Liakakos, Theodoros / Vaiopoulou, Anna / Apessou, Dimitra / Papaparaskeva, Kleo / Patapis, Pavlos / Dervenis, Christos. ·aSurgical Department-HPB Surgical Unit, Konstantopouleion Agia Olga General Hospital bLaboratory of Biology, Department of Basic Medical Science, School of Medicine, University of Athens cThird Department of Surgery, University of Athens School of Medicine, Attikon University Hospital, Athens, Greece. ·Eur J Gastroenterol Hepatol · Pubmed #24987821.

ABSTRACT: Pancreatic neuroendocrine tumors (PNETs) share a unique genetic identity, functional behavior, and clinical course. Compared with tumors of the exocrine pancreas, they are rare and show a different biologic behavior and prognosis. On the basis of data from recent studies, all PNETs, outside of small insulinomas, should be considered potentially malignant and treated accordingly. Untreated tumors have a high possibility to grow locally into adjacent structures or spread to distant organs. Although surgical excision irrespective of tumor functioning or nonfunctioning state remains the cornerstone of therapy, providing the best disease-free and survival rates to date, the understanding of the genetic nature of the disease yields new 'targets' to consider in drug development. The aim of this review is to summarize all recent advances of genetic research and new drug development in terms of PNETs, especially their genetic identity and subsequent alterations leading to the development of near or total malignant activity, and the new medical treatment strategies of this potentially curable disease on the basis of therapeutical agents acting, where possible, at the genetic level.

3 Article Expression Patterns of Growth and Survival Genes with Prognostic Implications in Advanced Pancreatic Cancer. 2016

Pectasides, Dimitrios / Kotoula, Vasiliki / Papaxoinis, George / Alexopoulou, Zoi / Dervenis, Christos / Samantas, Epaminontas / Papaparaskeva, Kleo / Charalambous, Elpida / Gkakou, Chrysoula / Agalianos, Christos / Kalogeras, Konstantine T / Pentheroudakis, George / Fountzilas, George. ·Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece pectasid@otenet.gr hecogoff@otenet.gr. · Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece. · Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece. · Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece. · Health Data Specialists Ltd., Athens, Greece. · First Department of Surgery, Konstantopoulio Agia Olga General Hospital, Athens, Greece. · Third Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece. · Department of Pathology, Konstantopoulio Agia Olga General Hospital, Athens, Greece. · Translational Research Section, Hellenic Cooperative Oncology Group, Data Office, Athens, Greece. · Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece. ·Anticancer Res · Pubmed #27919956.

ABSTRACT: AIM: The aim of this study was to evaluate the mRNA expression pattern of growth- and survival-related genes and assess their prognostic significance in patients with advanced pancreatic cancer. PATIENTS AND METHODS: In total, 98 patients were included in this retrospective translational research study and were evaluated for Kirsten rat sarcoma viral oncogene homolog (KRAS) mutational status, and v-akt murine thymoma viral oncogene homolog 1 (AKT1), AKT serine/threonine kinase 2 (AKT2), AKT serine/threonine kinase 3 (AKT3), cyclin D1 (CCND1), epidermal growth factor receptor (EGFR), mitogen-activated protein kinase 1 (MAPK1), hepatocellular growth factor receptor (MET), avian myelomatosis viral oncogene homolog (MYC), nuclear factor kappa B subunit 1 (NFKb1), phosphatase and tensin homolog (PTEN) and mechanistic target of rapamycin (FRAP1) genes mRNA expression. Among these patients, 73 received first-line gemcitabine combined with erlotinib (N=57) or gefitinib (N=16). RESULTS: KRAS mutation did not correlate with mRNA gene expression. Unsupervised hierarchical clustering according to mRNA gene expression successfully distinguished four prognostically distinct groups of tumors. Overexpression of all genes was associated with best prognosis, while suppression or heterogeneous expression patterns of the examined genes were associated with expression patterns of growth- and survival-related genes, classifying pancreatic tumors into distinct groups with possibly different outcomes.